Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 15/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1135695 | 0.86 | CCR1 (0.52) | CCR1CYP11B2CYP11B1LMNAPKM | |
| SCHEMBL1670263 | 0.85 | CCR1 (0.44) | CCR1 | |
| SCHEMBL1135952 | 0.83 | CCR1 (0.50) | CCR1CYP11B2CYP11B1LMNAPKM | |
| SCHEMBL1135667 | 0.81 | CCR1 (0.66) | CCR1CYP11B2CYP11B1 | |
| SCHEMBL27887460 | 0.79 | HPGD (0.43) | CCR1LMNATSHRKCNH2 | |
| SCHEMBL23449651 | 0.76 | CCR1 (0.52) | CCR1CYP11B2CYP11B1LMNAPKM | |
| SCHEMBL29810375 | 0.76 | CCR1 (0.52) | CCR1CYP11B2CYP11B1LMNAPKM | |
| SCHEMBL1361914 | 0.75 | CYP11B1 (0.54) | CCR1CYP11B2CYP11B1TSHRMAPT | |
| SCHEMBL19120605 | 0.74 | MEN1 (0.48) | CCR1CYP11B2CYP11B1TSHRMAPT | |
| SCHEMBL19119916 | 0.73 | L3MBTL1 (0.47) | CCR1CYP11B2CYP11B1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| EP-2491028-B1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2491028-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | CCR1 1/4885CYP11B2 1080/4885CYP11B1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.